Cellectis S.A. CLLS
Updated: 10 Aug 2026
No signal published yet
We already track Cellectis S.A. and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Cellectis S.A.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cellectis S.A. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Cellectis reported its second quarter 2026 financial results, ending the period with $169 million in cash and deposits expected to fund operations into Q4 2027. During the quarter, the FDA granted RMAT designation to lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia. Clinical development continues across the company's lead product candidates.
What Firelda Watch includes for Cellectis S.A.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Cellectis S.A.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cellectis S.A. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more